HT4 HEALTH TECHNOLOGY ASSESSMENTS: ARE THEY RELEVANT TO CLINICAL PRACTICE?  by Zhang, B & Van Staa, TP
identiﬁed 88 aspects as subunits of eight main domains. Agencies
show most similarities in the domain ‘organization’ (4 of 15
subunits), followed by ‘dissemination’ (2 of 9), ‘methods’ (2 of
20), ‘processes’ (1 of 11), and, scope’ (1 of 13). All subunits of
the domains ‘decision’, ‘implementation’ and ‘impact’ were dif-
ferent. Ranking in terms of productivity is misleading without
taking into account other aspects. CONCLUSIONS: We found
considerably more differences than similarities across agencies
and countries inﬂuenced by contextual aspects. This elementary
framework is intended to provide disaggregated and global com-
parative insight that may allow further progress in clariﬁcation
on the need for action regarding harmonization. By enlarging the
number of agencies assessed, our ﬁndings could facilitate the
communication between producers and users in an understand-
able, interpretable and transferable way.
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UPDATE OF RESULTS AND OUTCOMES OF NICE SINGLE
TECHNOLOGY APPRAISALS—ECONOMIC CRITICISMS
Karia R, Plested M, Cann K, Zwaferink H
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OBJECTIVES: The Single Technology Appraisal (STA) system
has attempted to shorten the process of assessment. As a
follow-up to a previous ISPOR poster, we sought to update the
database with since published STAs as well as conduct further
qualitative research and investigate the criticisms on the eco-
nomic aspects of the submissions. Discrepancies between ICERs
obtained by the manufacturer and the ERG group, and their
impact on outcomes were assessed. METHODS: A previously
developed database was updated with data from submissions
appraised between 6 December 2006 and 31 May 2008. Top-line
clinical data was extracted from the manufacturer submission,
evidence review group report, expert submission and the ﬁnal
appraisal determination. Further qualitative data was gathered to
capture criticisms on the economic aspects of the submissions.
Differences in ICER values between the manufacturer and the
ERG group were also collected. RESULTS: In total, 18 STAs
have been submitted to and appraised by NICE. Thirteen of the
18 submissions received positive guidance from NICE, recom-
mending the use of the drug in the NHS. Further investigation
into criticisms on the economic aspect revealed under-estimation
of costs, exclusion of relevant costs and/or adverse events and
concerns over the time horizon implemented resulting in an
under-estimation of the ICER, commonly leading to negative
guidance. Industry submissions reported ICERs ranging from
£4,726.00 to £44,600.00. Corresponding ICERs reported by the
ERG ranged from £8,500.00 to £458,000.00. The committee
provided positive guidance in approximately 50% of cases, even
though the ERG expressed concerns regarding aspects of the
economic model. CONCLUSIONS: Results demonstrated dis-
crepancies in ICERs between the manufacturer’s submission and
the ERG report. Fifty percent of the submissions received positive
guidance irrespective of concerns voiced by the ERG. Analyzing
criticisms on economic aspects of submissions alongside the ﬁnal
outcome will assist in educating manufacturers in the expecta-
tions of NICE.
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A COMPARISON OF REASONS FOR RECOMMENDATION AND
REJECTION IN FOUR HEALTHTECHNOLOGY APPRAISAL
SYSTEMS: NICE, SMC, CADTH AND PBAC
Cann K, Karia R, Plested M, Samuels E
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OBJECTIVES: Technology appraisal systems are used in many
countries to assess newly licensed drug treatments and devices.
Our objective was to identify the reasons underlying recent drug
appraisal decisions in four countries (England/Wales, Scotland,
Canada and Australia) where decisions differed between the
agencies. METHODS: Submissions appraised between 1 Novem-
ber 2005 and 31 May 2008 by NICE, SMC, CADTH and PBAC,
in England/Wales, Scotland, Canada and Australia respectively,
were searched for submissions with opposing decision outcomes.
We compared qualitatively and quantitatively the reasons for
rejection or recommendation for all drugs where decision out-
comes differed between HTA bodies. RESULTS: A total of 81
submissions were identiﬁed as having been appraised by two or
more of the HTA bodies with differing decision outcomes for the
same indication. Seven were excluded from the analysis due to
unavailability of data. The most common reasons given for rec-
ommendation of a drug were cost-effectiveness, superior efﬁcacy
to placebo, and superior efﬁcacy to comparators in 28, 14 and 13
submissions respectively. The most common reasons given for
rejection of a drug were a lack of cost-effectiveness, limitations
identiﬁed in the economic model submitted by the manufacturer,
and a lack of superior efﬁcacy to its comparators, as given in 21,
20 and 10 submissions respectively. Twenty-ﬁve of the submis-
sions highlighted the same issues pertaining to the new drug as
another HTA with a different decision outcome, but continued to
issue an alternative outcome. CONCLUSIONS: Commonly HTA
bodies focus on the relative cost-effectiveness and efﬁcacy of a
new drug. However, different HTAs place different emphases on
each aspect of a submission. Recognising the individual prefer-
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OBJECTIVES: Data from randomised clinical trials (RCT) are
often considered best evidence for health technology assessments.
The objective of this study was to compare event probabilities
used in published cost-effectiveness studies to those observed in
actual clinical practice. Selective Cox-2 inhibitors (coxibs) were
used as an example. Almost all the 30 published coxib cost-
effectiveness studies used RCT data for event probabilities.
METHODS: A basic cost-effectiveness model was developed
using a decision tree. Two alternative strategies were evaluated:
prescription of a conventional NSAID or coxib. The UK General
Practice Research Database (GPRD) was used to estimate the
individual probabilities of upper gastrointestinal (GI) events
during current use of NSAID or coxib. Outcomes included upper
GI events as recorded in GPRD and hospitalisation for upper GI
events recorded in the national registry of hospitalisations (Hos-
pital Episode Statistics) linked to GPRD. Incremental prescrip-
tions costs were based on GPRD costs. RESULTS: The study
population included over 1 million patients prescribed conven-
tional NSAIDs or coxibs. Only a minority of patients used the
drugs long-term and daily (34.5% of conventional NSAIDs and
44.4% of coxibs), whereas coxib RCTs required daily use for at
least 6–9 months. The rate of upper GI events (as recorded in
GPRD) and hospitalisations during current use of conventional
NSAIDs decreased over calendar time with 5–8% per year (tests
for linear trend P-value < 0.05). The mean cost of preventing one
upper GI event as recorded in GPRD was £52 k (ranging from
£32 k with long-term daily use to £91 k with intermittent use)
and £149 k for hospitalisations. The mean costs (for GPRD
events) over calendar time were £29 k during 1990–1993 and
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£87 k during 2002–2005. Using RCT data rather than GPRD
data for event probabilities, the mean cost was £8 k with the
VIGOR RCT and £10 k with the CLASS RCT. CONCLUSIONS:
The published cost-effectiveness analyses of coxibs lacked exter-
nal validity and did not represent patients in actual clinical
practice. External validity should be an explicit requirement in
cost-effectiveness analyses.




HOW MUCH SHOULD WE BE PREPAREDTO PAY FOR
PSYCHOSOCIAL INTERVENTIONS FOR PATIENTS WITH
ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)?
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OBJECTIVES: Notwithstanding evidence showing its clinical
effectiveness, little if any data have supported the cost-
effectiveness of psychosocial interventions for patients with
ADHD. The NIMH-initiated MTA study was designed to maxi-
mize clinical effectiveness of psychosocial interventions in chil-
dren with ADHD. We use patient-level data from this study to
estimate the maximum allowable cost of better-targeted behav-
ioral interventions that would still meet currently used bench-
marks for cost-effectiveness in Europe, assuming they replicate
clinical effectiveness as reported in the MTA study. METHODS:
A total of 579 children age 7–9.9 years with ADHD (DSM-IV)
were randomly assigned medication management (MedMgt),
intense behavioral treatment (Beh), both combined (Comb), or
community care (CC). All MTA treatment strategies were clini-
cally effective. Costing from a societal and from a third-party
payer’s perspective for Germany, The Netherlands, Sweden, and
UK excluded the research component of the study. Treatment
response was deﬁned as normalization of core symptoms after 14
months. QALYs were estimated using utility weights derived
from UK expert and parent-proxy-ratings. Comb was most effec-
tive, and Med dominated Beh economically. Using this data, we
estimated the maximum allowable cost (MAC) of Comb versus
Med, quantifying the uncertainty by means of non-parametric
bootstrapping. RESULTS: MACs and their 95% conﬁdence
intervals for Comb versus Med were determined (a) for ADHD,
and for subgroups with (b) “pure” ADHD (without comorbidity,
n = 184) and (c) hyperkinetic disorder (HKD, with or without
conduct disorder, n = 145), assuming (1) Comb meeting an ICER
threshold (when added to MedMgt) of (1) €50,000 or (2)
€100,000 per QALY. MACs for UK were (1) €2943 (€2569–
€3310) and (2) €3328 (€2612–€4043). Estimates for Germany
and The The Netherlands were lower, whereas Swedish estimates
were broadly in line with UK data. CONCLUSIONS: Despite
some limitations, which will be discussed, these estimates may
assist designing clinical studies to support acceptable cost-
effectiveness of psychosocial treatment strategies for ADHD.
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THE SUSTAINED DIAGNOSIS OF ATTENTION-DEFICIT
HYPERACTIVITY DISORDER FROM CHILDHOODTO
ADULTHOOD:A MEDICAID STUDY
Chen H, Sudharshan L
University of Houston, Houston,TX, USA
OBJECTIVES: To determine the percentage of patients who had
a continued diagnosis of attention-deﬁcit hyperactivity disorder
(ADHD) from childhood to adulthood in real practice and to
examine the association between the sustained diagnosis of
ADHD, other mental health comorbidities and the exposure to
psychotropic medications. METHODS: A retrospective longitu-
dinal analysis was conducted using the 1995 to 2001 Medicaid
claims data. The study cohort were patients 4–17 years of age
who received a diagnosis of ADHD in the year 1995. These
patients were then followed through 2001 to determine the per-
centage that retained the diagnosis of ADHD. Multivariate
regression analysis was employed to assess the association
between sustained ADHD diagnosis, other mental health
comorbidities (conduct disorder, oppositional deﬁant disorder,
mood disorders, anxiety disorder and substance abuse disorder)
and the exposure to psychotropic medications (stimulants,
antidepressants, antipsychotics, antianxiolytics, anticonvul-
sants). RESULTS: A total of 18,131 patients were identiﬁed with
a diagnosis of ADHD in 1995 and had continuous Medicaid
eligibility during the 7 year follow-up period. Out of those only
10,746(57.77%) retained a diagnosis of ADHD in the ﬁrst year
follow-up and merely 1530 (8.43%) retained the diagnosis of
ADHD in 2001. The length of retaining ADHD diagnosis is
positively associated with the early exposure to stimulants and
having mental health comorbidities such as mood disorders,
anxiety disorder, conduct disorder and oppositional deﬁant dis-
order. CONCLUSIONS: The result is in conﬁrmation with pre-
vious prospective studies which indicated that ADHD shows a
remission with maturation. However, the proportion of patients
retaining ADHD diagnosis in real practice is 60% to 80% lower
than the ﬁndings of those prospective studies, which suggests a
signiﬁcant gap between knowledge advancement and practice.
Further study is needed to clarify the relationship between psy-




METHYLPHENIDATE FORTREATMENT OF ATTENTION-
DEFICIT/HYPERACTIVITY DISORDER (ADHD) IN CHILDREN
AND ADOLESCENTS IN FINLAND:AN EVALUATION BASED
UPON A RANDOMIZED CLINICALTRIAL (RCT)
Schlander M1, Hjelmgren J2
1Institute for Innovation & Valuation in Health Care (InnoVal-HC),
Eschborn, Germany, 2Janssen-Cilag AB, Sollentuna, Sweden
OBJECTIVES: To evaluate the cost-effectiveness of methylpheni-
date (MPH)-OROS, a long-acting formulation given once daily
(o.a.d.), compared to short-acting MPH (immediate-release, IR),
which requires twice (b.i.d.) or thrice (t.i.d.) daily administration
schedules, from a payer’s perspective in Finland. METHODS:
Health care resource utilization was estimated based on the
Canadian ADHD RCT by Steele et al. (2006), comparing MPH-
OROS (average dose at study end, 37.8 mg/d; n = 70) with usual
care using MPH-IR (n = 73; hereof, 61% t.i.d., 34.6 mg/d; 39%,
b.i.d., 31.4 mg/d) in an open-label ‘pragmatic’ parallel-group
design over eight weeks. For costing, these data were combined
with Finnish unit costs. Effectiveness was deﬁned as intent-to-
treat remission rates as determined by parent ratings (primary
study endpoint: 18-item SNAP-IV scale). For an estimation of
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